Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review

Xenophon Kassianides BSc (Hons), MBBS, MRCP(UK), Sunil Bhandari MBChB, MRCP, FRCP, PhD, M Clin Edu, FHEA

Article Type

Review

Published

This review focues on the links between iron and phosphate metabolism, the most recent comparative studies between third-generation i.v. iron compounds, the important role of fibroblast growth factor 23 (FGF23), and the impact of hypophosphataemia on the patient. This review also presents an algorithm that can be used in patients requiring i.v. iron in anticipation of potential hypophosphataemia.

Read more

Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review

Giulia Cassone MD, PhD, Marco Sebastiani MD, Caterina Vacchi MD, PhD, Gian Luca Erre MD, Carlo Salvarani MD, Andreina Manfredi MD, PhD

Article Type

Review

Published

This review describes the available data and recent advances on the effectiveness and safety of MMF for the treatment of ILD related to RD, including rheumatoid arthritis, systemic sclerosis, primary Sjögren syndrome, systemic lupus erythematosus, idiopathic inflammatory myopathies, undifferentiated connective tissue disease, interstitial pneumonia with autoimmune features and antineutrophil cytoplasmic antibody-associated vasculitis.

Read more

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Karel Pavelka MD PhD, Zoltán Szekanecz MD PhD DSc, Nemanja Damjanov MD PhD, Branimir Anić MD PhD, Matija Tomšič MD PhD, Vadim Mazurov MD PhD, Marija Maksimovic MD, Orsolya Nagy MD PhD, Jerzy Świerkot MD PhD, Tzvetanka Petranova MD PhD, Tiina Veldi MD, Asta Baranauskaitė MD PhD, Catalin Codreanu MD PhD, Daina Andersone MD PhD, Roy Fleischmann MD

Article Type

Original Research

Published

This post hoc analysis of SELECT-COMPARE reports, for the first time, the efficacy and safety of upadacitinib 15 mg in combination with methotrexate
(MTX) in patients from the Central and Eastern European region with MTX inadequate response rheumatoid arthritis compared with placebo or adalimumab with MTX up to 48 weeks of follow-up.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.